title: Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity.
abstract: BACKGROUND
  Little is known of the importance of chromogranins (Cg) and secretogranins (Sg) in ulcerative colitis (UC). We therefore investigated fecal levels of CgA, CgB, SgII and SgIII, and their association with inflammatory activity, disease duration and medical therapy in UC.
  
  
  METHODS
  Analyses of CgA, CgB, SgII, SgIII and calprotectin in stool samples from 41 UC patients and 29 healthy controls were performed. Two stool samples, during relapse and remission, respectively, were obtained from each UC patient.
  
  
  RESULTS
  The levels of fecal CgA and SgII were higher in UC patients with active disease as compared to healthy controls. CgB and SgII were positively correlated with disease duration, but none of the granins were positively correlated with calprotectin, Mayo score, CRP or serum concentrations of TNF in UC patients with active disease. Also UC patients in remission had higher levels of CgA, CgB, SgII, and SgIII as compared to healthy controls. However, levels of fecal CgA, CgB, SgII and SgIII were lower during active disease relative to remission. Moreover, fecal levels of CgA and SgII were higher in UC patients in remission treated with thiopurines than in thiopurine-naïve patients in remission.
  
  
  CONCLUSIONS
  Fecal chromogranins and secretogranins are increased in UC but are not associated with disease activity, but seem to increase with duration of the disease. Thus, fecal granins might reflect structural changes associated with chronicity of disease, or medical therapy.
authors.affiliation: Dept. of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Sweden.
authors.forename: Hans
authors.initials: H
authors.lastname: Strid
authors.forename: Magnus
authors.initials: M
authors.lastname: Simrén
authors.forename: Anders
authors.initials: A
authors.lastname: Lasson
authors.forename: Stefan
authors.initials: S
authors.lastname: Isaksson
authors.forename: Mats
authors.initials: M
authors.lastname: Stridsberg
authors.forename: Lena
authors.initials: L
authors.lastname: Öhman
mesh_terms: D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D053379:Chromogranin A / Q000032:analysis*; D053378:Chromogranin B / Q000032:analysis*; D002864:Chromogranins / Q000032:analysis*; D003093:Colitis, Ulcerative / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D005243:Feces / Q000737:chemistry*; D005260:Female; D006801:Humans; D039841:Leukocyte L1 Antigen Complex / Q000032:analysis; D008297:Male; D008875:Middle Aged; D011687:Purines / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D053381:Secretogranin II / Q000032:analysis*; D012720:Severity of Illness Index; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D055815:Young Adult
chemical_list: D053379:Chromogranin A; D053378:Chromogranin B; D002864:Chromogranins; D039841:Leukocyte L1 Antigen Complex; D011687:Purines; D053381:Secretogranin II; D014409:Tumor Necrosis Factor-alpha; C506167:secretogranin III; D002097:C-Reactive Protein
keywords: Chromogranin; IBD; Secretogranin; Ulcerative colitis